Bladder Cancer News, Research Articles | Cancer Treatment Studies

Bladder Cancer


Latest Bladder Cancer News

Pembrolizumab Benefits Durable in BCG-Unresponsive High-Risk NMIBC

After a median time of 28.4 months, 40.6% of patients treated with pembrolizumab for high-risk nonmuscle-invasive bladder unresponsive to bacillus Calmette-Guérin (BCG) therapy had a complete response to the drug, and the median duration of response was 16.2 months.
Though early-stage bladder cancer is infrequently fatal, the decrease in recurrence rates has a mean

5-ARIs Do Not Lower Bladder Cancer Risk

Previous retrospective studies have suggested that 5-alpha-reductase inhibitors may beneficial effects on bladder cancer development and/or recurrence, but a prospective cohort study found no protective effect.
Next post in Bladder Cancer